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Summary 
Studies on isolated pancreatic islets suggest that Neuromedin U (NMU), a brain and 
gastrointestinal peptide, act as a decretin hormone, inhibiting glucose-stimulated insulin 
secretion. We investigated whether this effect could be reproduced in vivo and in isolated 
perfused rat pancreas. Unlike the incretin hormone, glucagon-like pepide-1 (GLP-1), 
intravenous NMU administration had no effects on blood glucose and plasma insulin and 
glucagon in vivo. Moreover, NMU neither changed insulin, glucagon, or somatostatin 
secretion from isolated perfused rat pancreas, nor affected GLP-1-stimulated insulin and 
somatostatin secretion. For NMU to act as a decretin hormone, its secretion should increase 
following glucose ingestion; however, glucose did not affect NMU secretion from isolated 
perfused rat small intestine, which contained extractable NMU. Furthermore, the two NMU 
receptors were not detected in endocrine rat or human pancreas. We conclude that NMU 
does not act as a decretin hormone in rats. 
Keywords: Decretin, glucagon-like peptide-1, neuromedin U, insulin secretion, type-2-
diabetes. 
 
 
 
 
 
 
 
 
 
3 
 
Introduction 
The peptide hormone, Neuromedin U (NMU), expressed in the brain and gastrointestinal 
tract in rats and humans (Augood et al., 1988; Austin et al., 1995; Ballesta et al., 1988; 
Domin et al., 1987; Fujii et al., 2000; Honzawa et al., 1990) has been reported to attenuate 
glucose-stimulated insulin secretion from isolated perfused rat pancreas and from perifused 
human pancreatic islets (Alfa et al., 2015; Kaczmarek et al., 2009; Kaczmarek et al., 2006).  
As this effect is opposite of that of the incretin hormones, glucagon-like peptide-1 (GLP-1) 
and glucose-dependent insulinotropic peptide (GIP), NMU was proposed to be a decretin 
hormone. However, the underlying mechanisms responsible for the proposed decretin effect 
were unclear, and more importantly, it is unknown whether the inhibitory effect of NMU on 
insulin secretion occurs in a physiological setting. We reasoned that for NMU to act as a 
decretin hormone during physiological circumstances, it should be secreted from the gut in 
response to at least glucose ingestion and to circulate in sufficient amounts to influence the 
endocrine pancreas, but NMU has proven difficult to measure in plasma and is generally 
considered a locally acting neuropeptide (Greenwood et al., 2011), which would be 
incompatible with a decretin function of NMU in the strict sense. If NMU can be 
demonstrated to be secreted from the gastrointestinal tract in response to glucose, it might 
indeed act as a decretin hormone with postprandial insulin secretion being regulated in a 
balance between stimulatory incretin and inhibitory decretin hormones, but evidence for 
this is lacking. This question is particularly relevant for the regulation of insulin secretion 
after gastric bypass surgery, where it is debated whether the postoperative improvement in 
glucose tolerance is due to prevention of the actions of a duodenal decretin hormone (the 
upper gut hypothesis) or promotion of the secretion of incretin hormones (the lower gut 
hypothesis) (Rubino et al., 2006a; Salinari et al., 2017). However, peripheral NMU 
injections have been reported to stimulate GLP-1 secretion in mice and to improve glucose 
tolerance and enhance insulin secretion, which would seem incompatible with the proposed 
decretin action of NMU (Peier et al., 2011). The purpose of the present study was to 
investigate the potential decretin actions of NMU in a relevant physiological setting. To this 
end, we carried out in vivo studies in rats and supplemented with studies of isolated 
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perfused rat pancreas and small intestine, which allow assessment of the direct effects of 
NMU on the secretion of glucagon, insulin and somatostatin (SST) from the pancreas (by 
excluding potential, confounding systemic factors) as well as measurement of a possible 
effect of NMU on GLP-1 secretion from the small intestine, and determination whether 
NMU is secreted from the gut upon luminal glucose exposure. 
Results 
Effects of intravenous NMU on blood glucose and insulin and glucagon secretion in the              
rat. 
To investigate whether NMU has effects on blood glucose and glucagon and insulin 
secretion in a physiological setting, we challenged anesthetized rats with intravenous 
glucose (1g/kg) alone or together with NMU (21 nmol/kg), GLP-1 (2 nmol/kg) or 
NMU+GLP-1. 
Blood glucose: Baseline blood glucose concentrations did not differ between groups 
(glucose = 8.8±0.2, glucose + GLP-1 = 9.1±0.2, glucose + GLP-1 + NMU = 10±0.6, 
glucose + NMU = 9.4 ± 0.2, P>0.05 for all groups). Intravenous glucose administration 
increased blood glucose concentrations, peaking at 1 min after administration in all 
treatment groups. Administration of GLP-1 lowered peak blood glucose and iAUC values 
(peak value: glucose = 23±1.8 mM vs. glucose + GLP-1 = 19±1.5 mM, P=0.001, iAUC0-30 
min: glucose = 187±21 min×mM vs. glucose + GLP-1 = 122±19 min×mM, P =0.13; P=0.03 
by unpaired two-way t-test), Fig. 1A and B). Blood glucose excursions over the entire 
experiment were similar in the glucose and glucose + NMU groups (iAUC0-30min = 185±18 
min×mM, P>0.99 compared to glucose group, Fig. 1A and B), and NMU had no significant 
effect on the glucose lowering effects of GLP-1, (glucose+GLP-1+NMU, iAUC0-30min = 
158±24 min×mM, P=0.65 compared to glucose+GLP-1 group, Fig. 1A and B). 
Plasma insulin: Plasma insulin concentrations did not differ between groups at baseline 
(P>0.05). Glucose administration caused an instant and robust increase in plasma insulin, 
which was potentiated by 200-300% by GLP-1, both with respect to peak concentrations 
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and overall concentrations (iAUC0-30min: glucose = 84±9.6 min×ng/ml vs. glucose+GLP-1 = 
174±29 min×ng/ml, P<0.05, n = 10, Fig. 1.C and D). The potentiating effect of GLP-1 on 
glucose-stimulated insulin secretion was not significantly altered when NMU was co-
administered ((iAUC0-30min = 161±20 min×ng/ml glucose+GLP-1+NMU), PGlucose+GLP-1 vs. 
PGlucose+GLP-1+NMU   =0.97). Similarly, there was no difference between glucose + NMU and 
glucose alone on plasma insulin levels (iAUC’s = 104±22 min x ng/ml, P=0.91 compared 
to glucose alone, n = 10, Fig.1.D). 
Glucagon: Plasma glucagon was low at baseline (<4 pM for all groups) and did not change 
significantly at any time points in any of the groups in response to the treatments (P≥0.29 
between all groups) and the concentration profiles over the course were not significantly 
different either (iAUCs0-30min glucose = 100±25 min×pM vs. glucose+GLP-1 = 59.7±12 
min×pM vs. glucose+GLP-1+NMU = 58.2±9.9 min×pM vs. glucose+NMU = 85.7±15 
min×pM, P≥0.29 for all groups vs. glucose alone, n = 10, Fig. 1E and F).  
Effects of NMU on isolated perfused rat pancreas  
As NMU had no detectable effects on the secretion of glucagon or insulin in vivo, we next 
studied the potential effects of NMU on the secretion of these hormones using the isolated  
perfused rat pancreas. This model has superior sensitivity because the perfusate is collected 
from the vein draining the preparation meaning that secreted peptides do not reach the liver 
and systemic circulation were they may be exposed to extensive extraction, degradation and 
dilution.   
Insulin secretion increased approximately 3.5-fold when glucose was elevated from 3.5 to 
10 mM (total secretory outputs during 15 min perfusion: 3.5 mM glucose = 1960±165 pmol 
vs. 10 mM glucose = 6983±1503 pmol, P<0.01, n = 7, Fig. 2A.1 and 2A.2). In the same 
experiments NMU administration (100 nM) neither affected insulin secretion at 3.5 nor at 
10 mM glucose concentrations (Pbaseline vs. NMU response at 3.5 mM glucose  = 0.41, Pbaseline vs. NMU 
response at 10 mM glucose  = 0.22, n=7, Fig. 2A.1 and 2A.2). In control experiments, insulin 
secretion (at 10 mM glucose) approximately doubled in response to GLP-1 (total output at 
baseline (15 min) = 5602±692 pmol vs. total output during GLP-1 administration (15 min) 
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= 11581±1526 pmol, P<0.01, Fig. 2B.1 and 2B.2) and when administered twice in the same 
experiment, the second response was not significantly different from the first (total outputs: 
6357±1917 pmol vs. 7250±1957 pmol, P=0.56, Fig. 2B.3). In a separate line of 
experiments, GLP-1 administration resulted in a comparable increase in insulin secretion 
(Pbaseline vs. response<0.05) and the response was unaffected by co-administration of NMU 
(total outputs during 15 min: GLP-1 = 7367±1124 pmol vs. GLP-1+NMU = 7375±1215 
pmol, n =7, Fig. 2C.1-2C.3). In the same set of experiments glucagon and SST secretion 
were also investigated.  
Glucagon secretion responded to glucose concentrations in a pattern opposite that of 
insulin, decreasing by a factor of two in response to glucose elevation (total outputs during 
15 min: 449.0±101 vs. 262.6±39.8 pmol, P<0.05, Fig. 3A.1 and 3A.2), but neither GLP-1 
nor NMU affected its secretion (Fig. 3B,C). Somatostatin secretion increased by 
approximately 50% in response to increased glucose concentration (total baseline output 
(during 15 min) = 44.9±5.5 pmol vs. output at GLP-1 infusion (15 min) = 64.6±7.3 pmol, 
P<0.05, Fig. 3D.1 and D2). GLP-1 approximately doubled SST secretion (total output at 
baseline (15 min) = 57.7±4.5 pmol vs. total output during GLP-1 administration = 89.5±8.9 
pmol, P < 0.01, Fig. 3.E1 and 4.E2) and did so to a comparable extent when administered 
twice in the same experiment (total outputs = 24.0±4.5 vs. 21±5.7 = P=0.66, Fig. 3.E3). 
NMU had no effect on glucose- and GLP-1-stimulated SST secretion (P = 0.84, Fig. 3F1-
3).  
Gastrointestinal expression and secretion for NMU in the rat 
NMU was expressed in the duodenum, proximal jejunum, distal ileum and colon in the rat 
reaching tissue concentrations of ~20-50 pmol/g (sensitivity < 1 pmol/g). NMU was 
undetectable in extracts of the esophagus and ventricle (Fig. 5A). Despite the relevant 
amounts of NMU in the extracts of the small intestine, no measurable NMU was detected in 
venous effluents from the perfused gut, neither at baseline nor in response to infusion of 
luminal glucose (20% v/w) (data not shown, n =6) although the sensitivity would have 
allowed detection of increases in the effluent concentration of less than 2 pmol/l. In 
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contrast, GLP-1 was secreted in significant amounts under basal conditions and its 
secretion increased approximately 8-fold in response to luminal glucose (P < 0.001 
compared to  baselines (Kuhre et al., 2017)).   
 
Control for bioactivity of the applied NMU  
To ensure that the lack of effects of NMU on pancreatic hormone secretion was not 
attributable to lack of activity of the synthetic NMU peptide applied in the different 
experiments, we tested the ability of the same peptide to activate the rat NMUR1 via the Gq 
pathway. In COS-7 cells transiently expressing the rat NMUR1, the peptide (rat NMU-23) 
activated the receptor with a potency of 19 nmol/l (logEC50 -7.7±0.11, n=3: Fig. 4B).  
 
NMUR1 and NMUR2 expression in the pancreas 
For NMU to act directly on the endocrine pancreas, one of the two NMU receptors has to 
be expressed here. Thus, we investigated the expression of the two NMU receptors, 
NMUR1 and NMUR2, by qPCR. In both rat and human islets, NMUR1 expression was 
below detection limit (Ct-value > 33). NMUR2 expression was minimal, but detectable, in 
human and rat islets and was approximately 25 and 43-folds lower than the respective 
expression of GLP-1R (Ct-value GLP-1R: human = 27.9±0.55, rats = 22.6±0.12) (Fig. 5C, 
D). In addition, we investigated NMUR1 and NMUR2 expression in sorted human alpha, 
beta and delta-cells. Expression levels were extracted from published single cell RNA 
sequencing databases, originating from 3 different populations (combined n = 26)  (Muraro 
et al., 2016; Segerstolpe et al., 2016; Xin et al., 2016). NMUR1 and NMUR2 were not 
detected in any of the endocrine cell types, but GLP-1R (positive control) was detected in 
both beta and delta cells (Fig. 4E).  
Consistent with the lack of expression, NMUR1 could not be detected in the rat pancreas by 
immunohistochemistry, and was also absent islets (Fig. 4E and supplementary figure 1), but 
the receptor was expressed in the small intestine (Fig. 4F). NMUR2 was also not detected 
in the pancreatic islets (or the small intestine), but it was detected in the exocrine rat 
pancreas (Fig. 4E).  
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No effects of NMU on GLP-1 secretion from isolated perfused rat small intestine 
NMU has been reported to stimulate GLP-1 secretion in mice when administered 
peripherally (Peier et al., 2011). To investigate whether this effect is a direct effect of NMU 
actions on the gut, we administered NMU-23 to isolated perfused rat small intestine. NMU 
did not affect GLP-1 secretion (baseline secretion: 233.8 ± 93.5 pmol/15 min vs. NMU = 
308.5 ± 123.9 pmol/15 min, P=0.57, n=5) although the positive control, taurine-
deoxycholic acid, increased secretion 4-fold (from 405.6 ± 151 pmol/15 min to 1391 ± 324 
pmol/15 min; Supplementary fig. 2A-C).  
Discussion 
NMU is a neuropeptide predominately expressed in the brain and small intestine (Augood 
et al., 1988; Domin et al., 1987). It was reported to attenuate glucose-stimulated insulin 
secretion from in situ perfused rat pancreas and perifused human islets (Alfa et al., 2015; 
Kaczmarek et al., 2009; Kaczmarek et al., 2006), which led to the proposal that NMU 
represents a new physiologically relevant inhibitory factor. One of the theories offered to 
explain the anti-diabetic outcome of gastric bypass surgery is that secretion of an upper 
intestinal decretin factor is eliminated by the bypass (Rubino et al., 2006b). Therefore, it 
was proposed (Alfa et al., 2015; Kaczmarek et al., 2009; Kaczmarek et al., 2006) that one 
such factor could be NMU. The studies leading to this proposal were based on in situ 
perfused rat pancreas and perifused isolated human islets. In the perfusion study, the 
attenuating effect of NMU appeared to be mediated indirectly by NMU-stimulated SST 
secretion (through activation of NMUR1 on the pancreatic δ-cell)(Kaczmarek et al., 2009), 
while the study on perifused human islets (Alfa et al., 2015) concluded that the decretin 
effect of NMU resulted from a direct effect on the β-cell, as in that study, NMUR1 was 
found to co-localize with insulin but not with glucagon or SST. Besides this apparent 
inconsistency regarding its mechanism of action, two additional observations  question the 
potential decretin role of NMU: 1) peripheral administration of NMU in mice was reported 
to stimulate GLP-1 secretion and improve glucose-tolerance after OGTT (Peier et al., 
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2011), which must be assumed to counteract a decretin effect of NMU since GLP-1 is a 
potent enhancer of glucose-stimulated insulin secretion,  and 2) the majority of studies 
regarding NMU-receptors have shown that NMUR1 and -2 couple to Gq/11(Raddatz et al., 
2000; Shan et al., 2000; Szekeres et al., 2000), meaning that activation of the receptors will 
result in the production of IP3 (inositol trisphosphate) and DAG (diacylglycerol) which 
would be associated with stimulation of insulin secretion (Straub and Sharp, 2002). 
However, most importantly, it remained unknown whether NMU acts as a decretin under 
physiological conditions. Therefore, we examined the effects of NMU on blood glucose 
and plasma glucagon and insulin in rats challenged with an intravenous glucose bolus 
(delivered intravenously in order to avoid secretion of GLP-1 from the gut). In this model, 
NMU had no effects on any of the parameters when administered alone and did not 
significantly counteract the glucose lowering effects of GLP-1. We next investigated 
whether glucose would stimulate the secretion of NMU from its primary site of expression 
– the intestine. Contradicting a physiological role of NMU as a decretin hormone, we 
detected no measureable NMU secretion from isolated perfused rat small intestine (both 
upper and lower small intestine were investigated separately), be it at basal conditions or in 
response to luminal glucose. In contrast, in the same experiments, luminal glucose 
stimulated the secretion of GLP-1 approximately 8-fold compared to baseline (to 400-500 
fmol/min) (Kuhre et al., 2017). Importantly, the lack of detectable NMU secretion is 
unlikely to be related to insensitivity of the assay we developed for measuring NMU as this 
assay reacts with endogenous rat NMU demonstrated by the measurements on gut biopsies 
and furthermore has a low detection limit (below 2 pmol/l). To unveil any potential direct 
effects of NMU on pancreatic hormone secretion with greater sensitivity, we also 
investigated the  effects of NMU on glucagon, insulin and SST secretion from the isolated 
perfused rat pancreas. Consistent with the in vivo study, NMU had no effects on the 
secretion of glucagon, insulin and SST, be it at  low or high glucose, and NMU also did not 
affect the stimulatory effects of GLP-1 on insulin and SST secretion. As NMU-23 has been 
shown to activate NMUR1 and -2 with comparable potency and efficacy (Brighton et al., 
2008), and since the concentration used was well above EC50 for both receptors, a clear 
response was expected, if the receptors were expressed. The reason for the different results 
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obtained by us and those obtained by (Kaczmarek et al., 2006), where NMU in a 
comparable experimental model was found to inhibit insulin secretion when administered 
in the same dose as in our study (100 nM) (Kaczmarek et al., 2006), is difficult to unravel. 
However,  the inhibitory effect (15-25%) elicited by  NMU was only clear when the 
pancreas was perfused at a supra-physiological glucose concentration (26.4 mM), whereas 
no effect was observed at a physiological glucose concentration (6.6 mM), closer to the 
glucose concentrations used in our studies (3.5 and 10 mM). The same authors later 
reported that the inhibitory effects of NMU on insulin secretion might be mediated via 
secretion of SST (Kaczmarek et al., 2009), but in that study SST secretion was only 
minimally affected by NMU (10-15% increase), and our data do not support a stimulatory 
role of NMU on SST secretion. Importantly, the lack of responses to NMU in our 
experiments is unlikely to reflect that inappropriate  NMU concentrations had been used or 
that the peptide was not bioactive, since NMUR1 was activated by the NMU-23 peptide 
used for the in vivo and perfusion studies with a potency (EC50) of 19 nM (in agreement 
with previously published results(Raddatz et al., 2000)). In the three studies reporting a 
decretin effect of NMU, the authors used NMU-25, whereas we used NMU-23. We chose 
to use NMU-23 rather than NMU-25, since NMU-23 is the molecular form of the peptide 
produced in rats (whereas NMU-25 is the form produced in humans).    
In addition to the negative functional data, we were unable to detect expression of the two 
NMU-receptors (NMUR1 and -2) in the endocrine pancreas (Islets of Langerhans) by 
immunohistochemistry. The three studies reporting a decretin effect of NMU did report 
NMUR1 expression but with striking inconsistency. In the study by Alfa and colleagues, 
NMUR1 was found expressed in the pancreatic β-cells, whereas Kaczmarek and colleagues 
located the receptor to the δ-cell (Alfa et al., 2015; Kaczmarek et al., 2009; Kaczmarek et 
al., 2006). Based on the available data, it is impossible to deduce whether the discrepancies 
between our results and the results published by Kaczmarek reflect differences in antibody 
specificity. Unfortunately, in the cited studies neither NMUR1 negative tissue nor tissues 
from NMUR1-/- mice were investigated. However, the anti-NMUR1 antibody used by Alfa 
and colleagues appears to be the same as the one we used, but while we find minimal 
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staining in the rat islets, they found a staining intensity in human beta cells comparable to 
the intensity of insulin staining. In our study, staining was evident in neurons in the rat 
brain (positive control), indicating that the negative findings in the pancreas were not due to 
technical issues. In order to look further into this inconsistency, we investigated NMUR1 
and NMUR2 expression in the islet by qPCR. In both rat and human islets, NMUR1 
expression was below detection limit whereas NMUR2 expression was low and very close 
to the detection limit. In support of this, RNA sequencing based NMUR1 and -2 
expressions in sorted human α, β and δ-cells, extracted from three public available 
databases (Muraro et al., 2016; Segerstolpe et al., 2016; Xin et al., 2016), showed no 
detectable expression of the receptors. In contrast, GLP-1R was, in agreement with other 
studies (Tornehave et al., 2008) expressed in β-cells but not α-cells. Again, this contrasts to 
the results presented by Alfa and colleagues, as they reported identification of NMUR1 
mRNA in human islets. Their expression data are difficult to assess as primer sequences 
were not provided. Furthermore, data are presented as delta-delta Ct-values normalized to 
expression in liver tissue (2.3 fold higher in islets), but the delta-Ct-value for liver 
expression was not reported which is unfortunate, as NMUR1 expression was previously  
reported undetectable in human liver tissue (Raddatz et al., 2000). The absolute level of 
expression in islets reported by Alfa et al. is therefore difficult to evaluate.  
Taken together, our study therefore demonstrates that NMU does not as act as a decretin 
hormone in rats and is unlikely to have any direct effects on the endocrine pancreas in 
humans. 
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Main figure titles and legends 
Fig. 1. Effects of GLP-1 and NMU on blood glucose clearance and plasma insulin and 
glucagon. Data are shown as means±SEM. A: Blood glucose (mM), C: Plasma insulin 
(ng/ml), E: Plasma glucagon (pM). Response to intravenous injection with glucose (black) 
glucose+GLP-1(brown), glucose+GLP-1+NMU (blue), and glucose+NMU (grey). B, D, F: 
iAUC’s of A, C and E, respectively. Stars above time points indicate difference between 
glucose group vs. glucose+GLP-1 group (brown stars) and glucose vs. glucose+GLP-
1+NMU group (blue stars). N = 10. Statistical significance was tested by One way ANOVA 
for repeated measurements followed by Bonferroni multiple comparisons test; *P < 0.05, 
***P < 0.001.   
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Fig. 2. Insulin secretion from isolated perfused rat pancreas is controlled by glucose 
levels and GLP-1 but not by NMU. Data are shown as means±SEM. A.1 and 2. Insulin 
secretion/output in response to NMU at 3.5 and 10 mM glucose. B.1-3: Insulin 
secretion/output (at 10 mM glucose) in response to GLP-1 (1 nM). C1-C3: Insulin secretion 
(at 10 mM glucose) in response to GLP-1 (1 nM) and NMU (100 nM).  Dots show results 
from respective experiments. Statistical significance was assessed by paired t-test; *P<0.05, 
**P<0.01, ****P<0.0001, n = 7.   
Fig. 3. Glucagon and somatostatin secretion from isolated perfused rat pancreas is 
controlled by glucose levels but not by GLP-1 or NMU. Data are shown as means±SEM. 
A.1 and 2. Glucagon secretion in response to NMU (100 nM) at 3.5 and 10 mM glucose. 
B.1-3: glucagon secretion (at 10 mM glucose) in response to GLP-1 (1 nM). C1-C3: 
glucagon secretion (at 10 mM glucose) in response to GLP-1 and GLP-1 (1 nM) + NMU 
(100 nM). D.1 and 2. Somatostatin secretion in response to NMU (100 nM) at 3.5 and 10 
mM glucose. E.1-3: Somatostatin secretion (at 10 mM glucose) in response to GLP-1 (1 
nM). F1-C3: Somatostatin secretion (at 10 mM glucose) in response to GLP-1 and GLP-1 
+ NMU (100 nM). Dots show results from respective experiments. Statistical significance 
was assessed by paired t-test *P<0.05, **P<0.01, n = 7. 
Fig. 4. NMU expression down the rat gastrointestinal tract, NMUR1 receptor 
activation and NMUR1 and -2 expressions in pancreas and gut.  A: Extractable NMU 
(total) concentrations down the gastrointestinal tract in the rat. B: NMUR1 receptor 
activation by synthetic rat NMU-23 in COS-7 cells transiently expressing the rat NMUR1 
(measured as IP3 formation). C: NMUR-1, NMUR-2, and GLP-1R expression in human 
islets. D: NMUR-1, NMUR-2 and GLP-1R expression in rat islets. . E: Expression of 
NMUR1, NMUR2 and GLP-1R in sorted human alpha-, beta-, and delta-cells islets (by 
single cell RNA sequencing). F: Representative NMUR1 and NMUR2 staining’s in rat 
pancreas and small intestine. Data in A and B are show as means±SEM. Dots in A indicate 
individual data points. “I” in subfigure E indicate pancreatic islets. Statistical significance 
was assessed by One way ANOVA for repeated measurements followed by Bonferroni 
multiple comparisons test (A, C and D), ; *P<0.05, **P<0.01, ****P<0.0001, n(A) = 7, 
n(B) = 3, n(C) = 6 n(D) = 5, n(E) = 27 (collected from three different populations), n(F) = 
4.  
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Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the Lead Contact, Prof. Jens Juul Holst (jjholst@sund.ku.dk). 
Experimental model and subject details 
Animal studies 
Ethical considerations: Animal studies were conducted with permission from the Danish 
Animal Experiments Inspectorate (2013-15-2934-00833) and approved by the local ethical 
committee and were conducted in accordance with the EU Directive 2010/63/EU and 
guidelines of Danish legislation governing animal experimentation (1987) and the NIH 
(publication number 85-23). 
 
Animals: Male Wistar rats were obtained (~250g) from Janvier (Saint Berthevin Cedex, 
France) and housed two-a-cage under standard conditions with ad libitum access to chow 
and water, following a 12:12h light and dark cycle. Rats were allowed to acclimatize for at 
least one week before the day of study. 
Cell line studies: COS-7 cells (non-human primate cell line, isolated from a male 
Chlorocebus aethiops (Green monkey)) were purchased at ATCC (Cat. No. CRL-1651) and 
cultured at 10% CO2 and 37°C in Dulbecco’s modified Eagle’s medium 1885 
supplemented with 10% foetal bovine serum, 2 mM glutamine, 180 units/ml penicillin, and 
45 g/ml streptomycin. 
 
Method details 
In vivo study: At the respective day of study, food was withdrawn just before the feeding 
period (the dark period, 1700h), meaning that rats were “semi-fasted” at the time of study. 
Rats were divided into weight matched groups and anesthetized by a subcutaneous injection 
with Hypnorm/midazolam (0.079 mg fentanyl citrate + 2.5 mg fluanisone + 1.25 mg 
midazolam/ml: 0.3 ml/100g body weight). The abdominal cavity was opened and a needle 
inserted into the inferior caval vein, blood (300 µL/time point) was withdrawn through this 
needle into EDTA coated syringes (cat. no. 03690, Sigma Aldrich) and samples were 
 
 
transferred to 1.5 ml EDTA-coated tubes (cat. no. 200 K3E, Microvette; Sarstedt, 
Nümbrecht, Germany). Between sample collections, the needle was flushed with isotonic 
saline to clean the needle and prevent clot formation (100 µL, room temperature). Samples 
were drawn at time -5, 0, 1, 2, 5, 10, 15, 30 min. In total 2.4 mL blood was withdrawn 
(corresponding to approximately 10% of the total blood volume). Approximately 0.8 mL 
isotonic saltwater was administered in total, compensating for approximately half of the 
fluid loss. Baseline samples were collected 5 min after insertion of the needle (-5min) and 
immediately before administration of test substance (0 min), which was gently injected 
through the needle over 5 seconds (total volume 1 mL). The rats received intravenously 
either 10% (w/v) glucose (1 mL/300g body weight ~ 0.3g in total), 10% glucose + 2 
nmol/kg GLP-1, 10% glucose + 2 nmol/kg GLP-1  + 21 nmol/kg NMU or 10% glucose + 
63 nmol/kg NMU. Rats from the same cage received different treatments. Blood glucose 
was measured immediately after collection as described below. The remaining sample was 
kept on ice, centrifuged within 15 min (1,650 g, 4°C, 10 min) and plasma was transferred to 
fresh Eppendorf tubes and stored at -20°C until hormone quantification. Weight did not 
differ between experimental groups (mean ± SEM:  glucose = 322±4.8g, glucose+GLP-1 = 
290±29g, glucose+GLP-1+NMU = 296±23g, glucose+NMU = 316±4.9g, n = 10, P > 0.05 
for all groups).  
 
Isolated perfused rat pancreas: Male Wistar rats (~350g) were obtained from Janvier and 
housed and anesthetized as described above. The entire large intestine and the small 
intestine were removed after tying off the supplying vasculature, leaving only the proximal 
duodenum connected to the pancreas in situ. Furthermore, the spleen and stomach were 
removed and the kidneys were excluded from the isolation by tying off the renal arteries. 
The abdominal aorta was tied off just below the diaphragm and immediately after a catheter 
was inserted retrogradely into the abdominal aorta just proximal to the renal arteries, so that 
the aorta now exclusively supplied the pancreas (through both the coeliac- and the superior 
mesenteric artery). The pancreas was perfused with perfusion buffer (5.0 ml/min) which 
had been heated to 37°C and oxygenated with 95% O2, 5% CO2 prior to perfusion (resulting 
in maximal O2 saturation and a pH of 7.3-7-4) by use of a UP100 Universal Perfusion 
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System from Hugo Sachs (Harvard Apparatus, March Hugstetten, Germany). Venous 
effluent samples were collected each minute from a catheter inserted into the portal vein. 
Immediately after establishment of perfusion, the rat was euthanized by perforation of the 
diaphragm. The preparation was allowed to stabilize for approximately 30 min before the 
experiment was started. Test stimulants consisted of 1 nM GLP-1, 100 nM NMU and 10 
mM L-arginine provided by the manufacturers specified below. All stimulants were diluted 
in perfusion buffer without addition of solubilizers. L-arginine, a well-known stimulator of 
glucagon, insulin and somatostatin secretion, was infused at the end of all experiments as a 
positive control for pancreas responsiveness. Perfusion pressure and output were closely 
monitored throughout the experiment and used as an indication of the wellbeing of the 
preparation. Both parameters remained stable during the perfusion. Methods are described 
in more details elsewhere (Christiansen et al., 2015).    
Isolated perfused rat small intestine: In brief, the small intestine was isolated and perfused 
from male Wistar rats (~250g) by a protocol that was similar to the pancreas perfusion 
protocol. Depending on the study, the entire small intestine was isolated (in the studies 
were synthetic NMU was administered) or the upper or lower half of the small intestine 
was isolated (in the studies were luminal glucose was administered). In contrast to the 
pancreas perfusion studies, the intestine was perfused only through the upper mesenteric 
artery, which does not supply the stomach, spleen and kidneys – these organs were 
therefore left untouched. Only the large intestine and either the upper or lower half of the 
small intestine were removed after tying off the supplying vasculature. A plastic tube was 
inserted into the lumen of the remaining part of the intestine (either the upper of lower half) 
and the lumen cautiously flushed with isotonic saline followed by a continuous slow 
infusion (0.5 ml/min). The gut was perfused vascularly at a rate of 7.5 ml/min and venous 
effluent was collected each minute from the portal vein. Luminal glucose (20% w/v, in 
isotonic saline) was administered at an initial rate of 2.5 ml/min for the first three minutes 
(to quickly replace the saline in the lumen) and hereafter at 0.5 ml/ min for the remaining 
stimulus period. After stimulation the lumen was flushed with isotonic saline at 2.5 ml/min 
the first three minutes and then at 0.5 ml/min for the remaining time of the experiment. 
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Synthetic NMU-23 and tauro-deoxycholic acid (pos. control) was prepared in perfusion 
buffer and administered intra-arterially through a three-way cock-valve by use of a syringe 
pump. The method is described in more detail elsewhere (Kuhre et al., 2014b).    
Chemicals and peptides: GLP-1 (7-36NH2) and NMU (amidated rat NMU-23) were 
purchased from Bachem (Cat. no. 4016663 and 4030663, Weil am Rhein, Germany). D-
glucose and L-arginine were purchased from Sigma Aldrich (Cat. no. G9270 and A6969, 
Brøndby, Denmark). Peptides were initially dissolved in milliQ-water supplemented with 
1% (w/v) human serum albumin (HSA) (Cat. No. 12666, Millipore, Copenhagen, 
Denmark), in both cases to reach a concentration of 1 mM, and then diluted further in either 
isotonic saline supplemented with 10% glucose and 1% HSA (in vivo experiment) or in 
perfusion buffer (perfusion studies). Perfusion buffer was a modified Krebs-Ringer buffer 
supplemented with 0.1% (w/v) BSA (Fraction V; cat. no. 1.12018.0500, Merck, Ballerup, 
Denmark), 5% (w/v) dextran T70 to balance osmolarity (Pharmacosmos, Holbaek, 
Denmark) and 5 mM pyruvate, fumarate and glutamate and 3.5 or 10 mM glucose as 
indicated in the result section. The buffer was pH adjusted to 7.4-7.5.  
Immunohistochemistry: Antibodies: Alexa Fluor® 488 goat anti-rabbit IgG was from 
Invitrogen (cat. no. A-11008, Naerum, Denmark). Anti-NMUR1 (cat.no. ab121959) and 
anti-NMUR2 (cat.no. ab115549) antibodies were obtained from Abcam (Cambridge, 
United Kingdom). Intestine and pancreas tissue specimens from rats were fixed in 10% 
(w/v) formalin in 0.1 M phosphate buffer (pH 7.4) for at least 24 hours at 4°C. The tissue 
was dehydrated in ethanol and xylol and finally embedded in paraffin wax. 3 µm thick 
paraffin sections were cut for immunofluorescence and placed on Superfrost Plus glass 
slides. Before immunostaining, specimens were pretreated with 1 mM ethylene-diamine-
tetra-acetic acid (EDTA; pH 8.0) for 2 x 10 min at 475 W in a microwave oven. Anti-
NMUR1 and 2 were applied to the sections in 1:100 dilution overnight in a cold room. 
Wash was performed with PBS between each step. The secondary antibody (FITC 
conjugated) was added in dilution 1:1000 at room temperature for 1 hour, protected from 
visible light.  Immunofluorescence microscopy was performed with a Zeiss confocal 
microscope 510 equipped with a 63x objective or an inverted Zeiss Axiovert 220 Apotome 
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system with the same type of objectives. The images were processed using the Axiovision 
program (Carl Zeiss, Oberkochen, Germany) and the MetaMorph® software. 
Eﬀﬁﬂ ﬃﬂﬃ ﬀ! Pancreatic islets from non-diabetic one week old rats from rat islets 
("#5) were isolated as described previously(Nielsen et al., 1999) and kept at in RPMI-
Glutamax medium and incubated at 37°C, 95% O2, 5% CO2 for 72 hours/days before RNA 
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NMU concentrations in the rat gut: Gastrointestinal tissue biopsies (~1-1,5 cm) was 
collected from rats that had been housed and anesthetized as described above. Tissue was 
rinsed in PBS and snap frozen on dry ice before storage at -80°C. Tissue was homogenized 
by 1% trifluoroacetic acid (TFA) (cat no. TS-28904, Thermo Fisher Scientific, Fremont, 
USA) with a 5 mm steal bead and bead mill (TissueLyzer, Qiagen instruments AG, 
Hombrechtikon, Switzerland). Total protein concentrations were quantified by Pierce BCA 
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Protein Assay Kit (cat. no. 23227, Thermo Fisher Scientific, Fremont, USA). Extracts were 
purified using tc18 cartridges (cat. no. 036810 Waters, Massachusetts, United States) as 
previously described in details (Kuhre et al., 2014a). Samples were reconstituted in 1 ml of 
double buffer (phosphate buffer 80mM, 0,1 % Human Serum Albumin (cat. No. 12666, 
Merck KgaA, Darmstadt, Germany), EDTA 10 mM and Thimerosal 0,6 mM (cat. No. T-
5125, Sigma Aldrich), pH 7.5). NMU (total) was quantified described below and 
normalized to whole wall tissue weight as well as to total protein content (quantified with 
BCA-kit) as. The distribution pattern of NMU was similar between normalization 
procedures; data are presented as pmol/g tissue 
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YZ\-23:   COS-7 cells were maintained as described above and 
transiently transfection with the rat NMUR1 (untagged, from Origene, cat. no.  RN208112 , 
Rockville, MD, USA) was performed using the calcium phosphate precipitation method 
with the addition of chloroquine (Kissow et al., 2012). As we found the rat NMUR2 
subtype, but not the NMUR1 subtype in the rat pancreas, it would have been more relevant 
to perform these studies on cells transfected with the former subtype, but that seemed 
technically infeasible as several providers stated that the NMUR1-containing plasmid was 
unstable and highly likely to result in mutations and/or rearrangements when using standard 
methods. A previous study demonstrated that the rat NMUR1 and NMUR2 are equally 
sensitive to rat NMU-23 activation (Brighton et al., 2008).  
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  ¡¢ Public available RNA sequencing data set from (GSE85241, GSE81608 
and E-MTAB-5061)(Muraro et al., 2016; Segerstolpe et al., 2016; Xin et al., 2016) were 
used for this analysis. Reads Per Kilobase Million (RPKM) values for NMUR1, NMUR2 
and GLP1R from the respective data bases were uploaded to the Jupyter Notebook 
(http://jupyter.org/). Data were then log2 transformed and means were calculated for 
NMUR1, NMUR2 and GLP1R in alpha, beta and delta cells, respectively. Only non-
diabetic individuals were included in the analyses (combined sample size = 26). Further 
details about the donors, isolation of cells and RNA-sequencing methods please see the 
original studies (Muraro et al., 2016; Segerstolpe et al., 2016; Xin et al., 2016). 
Biochemical measurements 
In vivo study: Blood glucose was measured by a handheld glucometer (Accu-chek Compact 
plus device; Roche, Mannheim, Germany) and plasma insulin and plasma glucagon by 
ELISAs from Mercodia (Cat. no. 10-1250-01 and 10-1281-01, respectively, Uppsala, 
Sweden).  
Isolated perfused rat pancreas and intestine: Insulin concentrations in perfusion effluents 
were assessed by in-house radio-immuno-assay (RIA) (assay code 2006-3) which detects 
all bioactive forms of insulin as previously described (Brand et al., 1995). Glucagon 
concentrations were quantified using a C-terminally directed in-house RIA (assay code 
4305) (Ørskov et al., 1991) and somatostatin (SST) was measured using an in-house RIA 
employing a side-viewing antibody (code: 1758-5), which reacts with all molecular forms 
of SST that possess the mid sequence. Concentrations of NMU were measured using a 
novel in-house-developed RIA assay. Antiserum was raised in rabbits against a C-terminal 
fragment of NMU conjugated to keyhole limpet hemocyanin (KLH) via an N-terminal 
cysteine. The selected antiserum (code no. 18643) could be used in a final dilution of 1: 
£ 
 
750.000 and showed no cross-reaction with GLP-1 (7-36NH2), GLP-2, glucagon, insulin, 
somatostatin, neurotensin, motilin, PYY (3-36), pancreatic polypeptide, Exendin (9-39) and 
secretin in concentrations up to 6 nM. The evaluation of the assay specificity was in line 
with guidelines discussed and demonstrated previously(Albrechtsen, 2017). As standard we 
used synthetic rat NMU (cat no. 350285, Abbiotec, San Diego, CA) and the tracer was 
human NMU (cat no. H-5538, Bachem AG, Bubendorf, Switzerland) 125I-labeled using the 
standard stoichiometric chloramine T method. The assay sensitivity was below 2 pM and 
the intra assay coefficient of variation was below 10%.  
 
 
Quantification and statistical analysis: In vivo data are presented as means±SEM for the 
respective time points and as well incremental (AUC) values ± SEM. Perfusion data are 
presented as means ± SEM for the respective time points and as either mean outputs ± SEM 
or incremental output means± SEM as indicated. Incremental AUC/outputs were calculated 
by subtraction of baseline values, which for the in vivo experiments was defined as the 
means of -5 and 0 min concentrations in each animal.  For the perfusion studies incremental 
outputs were defined as  the difference between baseline outputs (for each animal defined 
as the mean value of the 10 subsequent observations leading up to the first test substance 
administration) and response outputs  (defined as the output in the period from start of test 
substance application until levels were returned to baseline). Significance between groups 
was assessed by one-way ANOVA for repeated measurements (in vivo experiments) 
followed by Tukey multiple comparisons test or by two-way paired t-test (perfusions), as 
also indicated in respective figure legends. P<0.05 was considered significant.  All raw 
datasets can be accessed at: note to editor: will be uploaded to Mendeley upon acceptance 
of manuscript.  
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Supplementary figure 1: NMUR1 expression in rat. A: Rat islet (indicated with “I), B: Acinus 
cells in the pancreas, C: crypt cells in the small intestine, D: neurons in the brain. Blue staining is 
DAPI (nuclei staining) and red staining is NMUR1. Scale bars: A = 50 µm, B: 70 µm, C = 40 
µm, D = 50 µm. 
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Supplementary figure 2: No effects of NMU-23 on GLP-1 secretion from isolated perfused 
rat small intestine. GLP-1 (total) secretion from isolated perfused rat small intestine (entire 
small intestine) in response to intra-arterial administration of NMU-23 (100 nM) and Tauro-
deoxycholic acid (TDCA, 100 µM), respectively. A: GLP-1 secretion during the time course of 
the study, B: Total GLP-1 output during baseline periods and during stimulation with NMU and 
TDCA, respectively.  Dots in B shows results from respective experiments. Data are shown as 
means±SEM. Statistical significance was assessed by One way ANOVA for repeated 
measurements; *P<0.05,  n =5. 
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